The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity

Nature Chemical Biology

Volumn 10, Issue 9, 2014, Pages 768-773

  Winter, Georg E ^a   Radic, Branka ^a   Mayor Ruiz, Cristina ^b   Blomen, Vincent A ^c   Trefzer, Claudia ^a   Kandasamy, Richard K ^a   Huber, Kilian V M ^a   Gridling, Manuela ^a   Chen, Doris ^a   Klampfl, Thorsten ^a   Kralovics, Robert ^a   Kubicek, Stefan ^a   Fernandez Capetillo, Oscar ^b   Brummelkamp, Thijn R ^a,c   Superti Furga, Giulio ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DNA; GENOMIC DNA; NILOTINIB; PLASMID DNA; SEPANTRONIUM BROMIDE; SLC35F2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON ADENOCARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG UPTAKE; ENDOPLASMIC RETICULUM; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE INTERACTION; GENETIC SCREENING; GENOTOXICITY; HAPLOIDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; MEDIAN EFFECTIVE CONCENTRATION; META ANALYSIS (TOPIC); MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CLONING, MOLECULAR; COMET ASSAY; DNA DAMAGE; GENOME, HUMAN; HAPLOIDY; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INTERCALATING AGENTS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, SCID; NAPHTHOQUINONES; RNA, NEOPLASM;

EID: 84906303888     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1590     Document Type: Article

References (34)

1. Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812-1821 (2010).
2. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783-1791 (2012).
3. Birsoy, K. et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45, 104-108 (2013).
4. Reiling, J.H. et al. A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin. Proc. Natl. Acad. Sci. USA 108, 11756-11765 (2011).
5. Lanthaler, K. et al. Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast. BMC Biol. 9, 70 (2011).
6. Dobson, P.D. & Kell, D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discov. 7, 205-220 (2008).
7. Kell, D.B., Dobson, P.D. & Oliver, S.G. Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov. Today 16, 704-714 (2011).
8. Giacomini, K.M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
9. Tolcher, A.W. et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 26, 5198-5203 (2008).
10. Giaccone, G. et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 27, 4481-4486 (2009).
11. Nakamura, N. et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol. Cell. Proteomics 11, M111.013243 (2012).
12. Carette, J.E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235 (2009).
13. Carette, J.E. et al. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat. Biotechnol. 29, 542-546 (2011).
14. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
15. Glaros, T.G. et al. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother. Pharmacol. 70, 207-212 (2012).
16. Sappal, D.S. et al. Biological characterization of MLN944: a potent DNA binding agent. Mol. Cancer Ther. 3, 47-58 (2004).
17. Cohen, S.N. & Yielding, K.L. Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc. Natl. Acad. Sci. USA 54, 521-527 (1965).
18. Bakkenist, C.J. & Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
19. Ishida, N. & Kawakita, M. Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). Pflugers Arch. 447, 768-775 (2004).
20. Song, Z. Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. Mol. Aspects Med. 34, 590-600 (2013).
21. Sarangi, A., Bupp, K. & Roth, M.J. Identification of a retroviral receptor used by an envelope protein derived by peptide library screening. Proc. Natl. Acad. Sci. USA 104, 11032-11037 (2007).
22. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
23. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
24. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
25. Hartwell, L.H., Culotti, J., Pringle, J.R. & Reid, B.J. Genetic control of the cell division cycle in yeast. Science 183, 46-51 (1974).
26. Minematsu, T. et al. Carrier-mediated uptake of 1-(2-methoxyethyl)-2- methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide(YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab. Dispos. 37, 619-628 (2009).
27. Minematsu, T., Iwai, M., Umehara, K., Usui, T. & Kamimura, H. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab. Dispos. 38, 1-4 (2010).
28. Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
29. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
30. Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184-2185 (2012).
31. Wang, L., Feng, Z., Wang, X., Wang, X. & Zhang, X. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics 26, 136-138 (2010).
32. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013).
33. Toledo, L.I., Murga, M., Gutierrez-Martinez, P., Soria, R. & Fernandez-Capetillo, O. ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 22, 297-302 (2008).
34. Gyori, B.M., Venkatachalam, G., Thiagarajan, P.S., Hsu, D. & Clement, M.V. OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2, 457-465 (2014).